A RARE Assam tea has sold for a world record price at auction in India, highlighting a boom for speciality teas while the industry as a whole is in crisis.
A two-kilogram lot of Maijan Orthodox Golden tea sold for Rs 141,002 ($2,035) on Wednesday (31).
An unidentified Belgian trader bought the tea through a local agent, an auction official said.
Guwahati Tea Auction Centre secretary Dinesh Bihani said it was a record price at auction, shattering the Rs 50,000 a kilogram paid for some Manohari Golden tea the day before.
Buyers from Germany, Britain, the US and Iran are active in the Assam market and higher prices are believed to have been paid in private sales.
Maijan Orthodox comes from 100-year-old bushes on plantations owned by Assam Company India Limited, one of the world's oldest tea enterprises.
The company is bouncing back from having been declared bankrupt last year when it was taken over by Indian tycoon BR Shetty.
"Rich in aroma and briskness, Maijan Golden offers a unique and exotic experience," Assam Company India director Sanjay Jain said.
Production is a "tedious process" however, he added.
"The buds are plucked on specific dates depending on climatic conditions, rolled by hand and dried in sunshine.
"The whole process is very natural and there is no machine involved," Jain said.
He said only 35 kilograms of the tea was produced this year and only two kilos were offered at this week's auction.
"We are very happy with the record price. It indicates that there are buyers for quality tea and this is good news for the tea industry in Assam," he said.
Assam Company India has 14 gardens across the northeast state and produces more than 10 million kilograms a year of black teas and other varieties including Jasmine.
While Maijan Orthodox and other rare speciality teas from the region are booming, the Indian Tea Association (ITA) this week appealed for state and federal government aid to keep up prices of more ordinary products.
It wants authorities to ban the expansion of tea production in at least five key areas.
The association paid for newspaper adverts which said the tea industry, which employs more than one million people, is in crisis.
"While the average selling price has almost remained stagnant, the average cost of production is increasing leading to incurring of loss by the gardens," the appeal said.
The ITA also appealed for public funds to promote Indian tea and for the fixing of minimum prices at auction based on the cost of production.
Assam accounts for more than half of India's tea production with more than 650 million kilograms coming each year out of the state's 850 tea gardens.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.